- GSK +2.24%
EMA accepts GSK’s Blenrep MAA for multiple myeloma for review
Yahoo Finance · 4 days ago
Pfizer
Search results
- 39.94Add to watchlist+0.88 (+2.24%)As of Fri. Jul 26, 2024 11:09 AM EDT · Nasdaq Real Time Price (USD) · Market open
- Open39.63High40.04Low39.59
- Mkt Cap81.45BP/E (TTM)14.22Div & Yield1.49 & 3.81%
- Prev. Close39.0752 Wk. Low33.6752 Wk. High45.93
What analysts are sayingTop storiesRelated stocks
Through our STEM investments, we aim to equitably increase children’s confidence in doing science and pursuing STEM careers. That's why we offer GSK Science in the Summer™, a free, inquiry-based science education program that helps students grow to love science. Learn more about our US charitable investments.
We are a focused biopharma company with strong momentum and big ambitions, to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.
GSK plc (an acronym from its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company with global headquarters in London.
Find the latest GSK plc (GSK) stock quote, history, news and other vital information to help you with your stock trading and investing.
We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.
GSK has a significant footprint in the US across commercial, R&D, manufacturing, and corporate functions. We employ ~15,000 people across the US and have two corporate hubs. Explore GSK in the US.
At GSK, we unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.
